Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Cornea / Ocular Surface, Business and Innovation, Health Economics and Policy

A Nose for OSD

With an estimated 16 million adults suffering from dry eye disease (DED) in the US alone, there is huge appetite for more effective and easy-to-use therapeutic options. The news of the OC-01 nasal spray being released by Oyster Point Pharma was welcome news to me, as I feel it will have a real impact on my patients’ outcomes. The spray promises to overcome a number of challenges in ocular surface disease (OSD) management, namely by offering both physicians and patients a unique delivery system.

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

About the Author

Elizabeth Yeu

Elizabeth Yeu is Assistant Professor at Eastern Virginia Medical School and Cornea, Cataract and Refractive Surgeon with Virginia Eye Consultants, VA, USA

Newsletter

Send me the latest from The Ophthalmologist.

Sign up now

Most Popular

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register